Developmental neurobiology: Implications for pediatric psychopharmacology

Canadian Journal of Psychiatry

Volumn 46, Issue 9, 2001, Pages 810-818

  Carrey, Normand ^a  

^a IWK HEALTH CENTRE   (Canada)

Author keywords

Developmental neurobiology; Neuroprotective; Neurotoxic; Pediatric psychopharmacology

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CLOZAPINE; COCAINE; FENFLURAMINE; FLUOXETINE; GROWTH FACTOR; HALOPERIDOL; IMIPRAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PAROXETINE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AKATHISIA; BRADYKINESIA; BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN MATURATION; CLINICAL TRIAL; DEVELOPMENTAL BIOLOGY; DYSTONIA; HUMAN; LIFESPAN; MANIA; MENTAL DISEASE; MOTOR DYSFUNCTION; NERVE CELL; NEUROBIOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PSYCHOPHARMACOLOGY; REVIEW; STRESS;

EID: 0035687769     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370104600904     Document Type: Review

References (89)

1. Functional brain reorganization in children
2. Developmental pharmacodynamics
3. Synaptic density in human frontal cortex - Developemental changes and effects of aging
4. Concurrent overproduction of synapses in diverse regions of the primate cerebral cortex
5. Brain development, VII. Human brain growth spans decades
6. The myelogenetic cycles of regional maturation of the brain
7. The development of brain and behavior
8. Postembryonic cell lineages of the nematode C elegans
9. Recent recognition and molecular delineation of apoptosis: Beginnings of a therapeutic revolution?
10. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus
11. Mechanisms of cortical development: A view from mutations in mice
12. Riding the glial monorail: A common mechanism for glial guided neuronal migration in different regions of the developing mammalian brain
13. Genetic disturbances of neuronal migration: Some examples from the limbic system of mutant mice
14. Development of the catechoamine neurons in human embryos and fetuses, with special emphasis on the innervation of the cerebral cortex
15. The development of the primate neocortex - An overview
16. An immunohistochemical study of serotonin neuron development in the rat: Ascending pathways and terminal fields
17. Catecholamine innervation of the human cerebral cortex as revealed by comparative immunochemistry of tyrosine hydroxylase and dopamine-beta-hydroxylase
18. Transient postnatal elevation of serotonin levels in mouse neocortex
19. Positron emission tomography study of human brain functional development
20. Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: A possible model of neurodevelopmental disorders with cognitive deficits
21. Roles for serotonin in neurogenesis
22. Serotonin as a developmental signal
23. Effects of p-chlorophenylalanine on time of neuronal origin during embryogenesis in the rat
24. Dose-related effects of pre-natal 5-methoxytryptamine on development of serotonin terminal density and behavior
25. Serotonin promotes region-specific glial influences on cultured serotonin and dopamine neurons
26. Prenatal treatment with SKF 38393, a selective D1 agonist: Long term consequences on 3H-paroxetine binding and on dopamine and serotonin receptor sensitivity
27. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine
28. Inhibition of striatal acetylcholine release by serotonin and dopamine after the intracerebral administration of 6-hydroxydopamine to neonatal rats
29. Role of serotonin and other neurotransmitter receptors in brain development: Basis of developmentla pharmacology
30. Astroglial 5-HT-1a and S-100beta in development and plasticity
31. Impaired striatal dopamine receptor development: Differential D-1 regulation in adults
32. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine
33. Ontogeny of dopaminergic function in the rat midbrain tegmentum, corpus striatum and frontal cortex
34. Developmental regulation of 5-HT-2 and 5-HT-1C MRNA and receptor levels
35. Ontogeny of the serotonergic projection to rat neocortex: Transient expression of a dense innervation to primary sensory areas
36. Evaluation of age-related changes in serotonin 5-HT-2 and dopamine D2 receptor availability in healthy human subjects
37. Autoradiographic analysis of age dependent changes in serotonin 5-HT-2 receptors in human brain post-mortem
38. Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to the extent of brain dopamine depletion
39. Ontogenic developemnt of brain asymmetry in dopaminergic neurons
40. Dopaminergic neuron development in rats: Biochemical study from prenatal life to adulthood
41. An isolated growth cone-enriched fraction from developing rat brain has substance P binding sites
42. Dopamine D1 receptor evelopement depends on endogenous dopamine
43. Human brain dopamine receptors in children and aging adults
44. The detection of age-related decrease of dopamine D1 and D2 and serotonin 5-HT-2 receptors in living human brain
45. Postnatal development of striatal dopamine function
46. Neural development is regulated by classical neurotransmitters: Dopamine D2 receptor stimulation enhances neurite outgrowth
47. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain
48. Sex differences in dopamine receptor overproduction and elimination
49. Regulation of neurogenesis by growth factors and neurotransmitters
50. GABA and glutamate depolarize cortical progenitor cells and inhibit DNA synthesis
51. Blockade of NMDa receptors increases cell death and birth in the developing rat dnetate gyrus
52. The ontogeny of brain receptors for corticotropin releasing factor and the development of their functional association with adenylate cyclase
53. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders
54. Corticotropin-releasing factor-containing axon terminals synapse onto catecholamine dendrites and may presynaptically modulate other afferents in the rostral pole of the nucleus locus ceruleus in the rat brain
55. Hypothalamic-pituitary adrenal dysregulation in sexually abused girls
56. Early postnatal experience alters hypothalamic corticotropin-releasing factor mRNA, median eminence CRF content and stress-induced release in adult rats
57. The effects of neonatal rearing environment on CRF mRNA and CRF receptor levels in adult rat brain
58. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression
59. A molecular and cellular theory of depression
60. Stress and hippocampal neurogenesis
61. Physiological and cognitive effects of child abuse
62. Methylphenidate and brain dopamine neurotoxicity
63. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters
64. Is methylphenidate like cocaine
65. Striatal dysfunctionin attention deficit and hyperkinetic disorder
66. Selective effects of methylphenidatein attention deficit hyperactivity disorder: A functional magnetic resonance study
67. Methyulphenidate increased regional cerebral blood flow in subjects with attention deficit/hyperactivity disorder
68. Chronic fluoxetine treatment increases hippocampal neurogenesisin rats: A new theory of depression
69. Reduced effect of antidepressant on prolactin response to a serotonin agonist in prepubertal rats
70. Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life
71. Pharmacotherapyof adolescent major depressive disorder: Beyond TCAs
72. A double blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression
73. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized controlled trial
74. Serotonin selective reuptake inhibitorsin child and adolescent psychopharmacology: A review of published experience
75. Double-blind trial of fluoxetine and placebo in children and adolescents with obsessive compulsive disorder
76. Caudate glutamatergic changes with paroxetine therapy for obsessive compulsive disorder
77. Basal ganglia and treatment response in pediatric in pediatric obsessive compulsive disorder
78. Decrease in thalamic volumes in pediatric patients with obsessive compulsive disorder who are taking paroxetine
79. Effects of pre and postnatal haloperidol administration to pregnant and nursing rats on brain catecholaminelevels in their offspring
80. Enduring changes in dopamine receptor cells of pups from drug administration to pregnant and nursing rats
81. Periadolescence: Age-dependent behavior and psychopharmacological responsivity in rats
82. Initial anticholinergic prophylaxis for acute neuroleptic induced extrapyramidal syndromes
83. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients
84. Neuroleptic-related dyskinesias in autistic children: A prospective longitudinal study
85. Tardive and withdrawal dyskinesia in autistic children: A prospective study
86. Neuroleptic malignant syndrome in children and adolescents: Two case reports and a warning
87. Childhood-onset schizophrenia: Brain MRI rescan after 2 years of clozapine maintenance treatment
88. Changes in caudate volume with neuroleptic treatment
89. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs